{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:06:43Z","timestamp":1779692803990,"version":"3.53.1"},"reference-count":55,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      agonist guanfacine extended-release (GXR) in children and adolescents with generalized anxiety disorder (GAD), separation anxiety disorder (SAD), or social phobia\/social anxiety disorder.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Youth aged 6\u201317 years with a primary diagnosis of GAD, SAD, and\/or social anxiety disorder were treated with flexibly dosed GXR (1\u20136\u2009mg daily,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200962) or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200921) for 12 weeks. The primary aim of this study was to determine the safety and tolerability of GXR in youth with anxiety disorders, which involved the analysis of treatment-emergent adverse events (TEAEs), the emergence of suicidal ideation and behaviors, vital signs, and electrocardiographic\/laboratory parameters. Exploratory efficacy measures included dimensional anxiety scales (Pediatric Anxiety Rating Scale [PARS] and Screen for Child Anxiety Related Emotional Disorders [SCARED]), as well as the Clinical Global Impression\u2013Improvement (CGI-I) scale. As this was an exploratory study, no inferential statistical analyses were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>GXR was safe and well tolerated. Treatment-related mean\u2009\u00b1\u2009standard deviation changes in heart rate (GXR: 1.8\u2009\u00b1\u200912 beats per minute [bpm] decrease; placebo: 0.5\u2009\u00b1\u200911\u2009bpm decrease), systolic blood pressure (GXR: 2.3\u2009\u00b1\u200911\u2009mm Hg decrease; placebo: 1.7\u2009\u00b1\u200911\u2009mm Hg decrease), or diastolic blood pressure (GXR: 1.3\u2009\u00b1\u20099\u2009mm Hg decrease; placebo: 0.9\u2009\u00b1\u20097\u2009mm Hg increase) were similar between treatment groups. TEAEs, including headache, somnolence\/fatigue, abdominal pain, and dizziness, were consistent with the known safety profile of GXR. No differences were observed between treatment groups for PARS and SCARED scores, although at endpoint, a higher proportion of subjects receiving GXR versus placebo demonstrated CGI-I scores \u22642 (54.2% vs. 31.6%), as rated by the clinician investigator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>GXR was well tolerated in pediatric subjects with GAD, SAD, and\/or social anxiety disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:uri>\n                      <jats:italic toggle=\"yes\">Identifier:<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>NCT01470469.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2016.0132","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T14:41:08Z","timestamp":1486392068000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":55,"title":["Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial"],"prefix":"10.1177","volume":"27","author":[{"given":"Jeffrey R.","family":"Strawn","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott N.","family":"Compton","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Robertson","sequence":"additional","affiliation":[{"name":"Shire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Albano","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamdani","sequence":"additional","affiliation":[{"name":"Shire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira A.","family":"Rynn","sequence":"additional","affiliation":[{"name":"New York Presbyterian Morgan Stanley Children's Hospital, Columbia University\/New York State Psychiatric Institute, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Edited by Rockville Guy W.MD U.S. Department of Health Education and Welfare 1976 pp 218\u2013222."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00006"},{"key":"e_1_3_3_4_1","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th ed. Text Revision. Washington DC American Psychiatric Association 2000."},{"key":"e_1_3_3_5_1","first-page":"45","article-title":"Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale","volume":"85","author":"Arnsten AF","year":"2012","unstructured":"Arnsten AF, , Jin LE: Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale. Yale J Biol Med, 85:45\u201358, 2012.","journal-title":"Yale J Biol Med"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0098"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2009.06.002"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.177"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3695"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199704000-00018"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(00)00306-3"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2012.05.002"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181b26e9f"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.0.CO;2-J"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00531-0"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20039"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200005000-00009"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0035458"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-4-1"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000246070.23695.06"},{"key":"e_1_3_3_21_1","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor DF","year":"2010","unstructured":"Connor DF, , Findling RL, , Kollins SH, , Sallee F, , Lopez FA, , Lyne A, , Tremblay G: Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs, 24:755\u2013768, 2010.","journal-title":"CNS Drugs"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0075"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0192"},{"key":"e_1_3_3_24_1","first-page":"455","article-title":"The Pediatric Daytime Sleepiness Scale (PDSS): Sleep habits and school outcomes in middle-school children","volume":"26","author":"Drake C","year":"2003","unstructured":"Drake C, , Nickel C, , Burduvali E, , Roth T, , Jefferson C, , Pietro B: The Pediatric Daytime Sleepiness Scale (PDSS): Sleep habits and school outcomes in middle-school children. Sleep, 26:455\u2013458, 2003.","journal-title":"Sleep"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0122"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.4186"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1902"},{"key":"e_1_3_3_28_1","unstructured":"INTUNIV\u00ae (guanfacine) extended-release tablets [package insert]. Wayne PA Shire Pharmaceuticals LLC 2011."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1207\/S15374424JCCP3003_4"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200911030-00003"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2010.01.009"},{"key":"e_1_3_3_32_1","first-page":"1099","article-title":"Alpha 2 adrenergic agonists","volume":"45","author":"Newcorn JH","year":"1998","unstructured":"Newcorn JH, , Schulz K, , Harrison M, , DeBellis MD, , Udarbe JK, , Halperin JM: Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am, 45:1099\u20131022, 1998.","journal-title":"Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.06.006"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/23.8.1d"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.1.56"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16020225"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20769"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.2.290"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.2008"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.171"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.04.006"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.09.399"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.01.008"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2012.05.003"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.21913"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22329"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00569-0"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804633"},{"key":"e_1_3_3_51_1","first-page":"1279","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","author":"Walkup JT","year":"2001","unstructured":"Walkup JT, , Labellarte MJ, , Riddle MA, , Pine DS, , Greenhill L, , Klein R, , Davies M, , Sweeney M, , Abikoff H, , Hack S, , McCracken J, , Bergman L, , Piacentini J, , March J, , Compton S, , Robinson J, , O'Hara T, , Baker S, , Vitiello B, , Ritz L, , Roper M: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med, 344:1279\u20131285, 2001.","journal-title":"The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-015-0591-z"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1521\/capn.2014.19.5.7"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2011.10.012"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200109000-00018"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291703008158"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2016.0132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2016.0132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2016.0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:58:52Z","timestamp":1779692332000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2016.0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1089\/cap.2016.0132"],"URL":"https:\/\/doi.org\/10.1089\/cap.2016.0132","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}